ImmunityBio (IBRX) Stock Rises 39.75% on 700% Anktiva Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy IBRX?
Source: NASDAQ.COM
- Anktiva Revenue Surge: ImmunityBio reported approximately $113 million in net product revenue for Anktiva in 2025, reflecting a staggering 700% year-over-year growth, indicating strong market demand in cancer immunotherapy that may attract more investor interest.
- Positive Clinical Trial Progress: The company shared encouraging results from its bladder cancer drug trial, reinforcing market expectations for future approval applications, thereby boosting investor confidence and potentially driving further stock price increases.
- Significant Trading Volume: Trading volume reached 176 million shares, about 1,254% above the three-month average, indicating strong market interest in ImmunityBio, likely influenced by the closing of short positions.
- Stock Price Recovery Context: Despite an 85% decline since its IPO in 2015, the recent 39.75% increase in stock price not only reflects a positive response to the company's fundamentals but also optimistic expectations regarding future commercialization efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.100
Low
5.00
Averages
7.33
High
9.00
Current: 7.100
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly overstating Anktiva's capabilities, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its leadership in the field.
- Investor Guidance: Investors are advised to select counsel with a proven track record to ensure optimal representation in class actions, avoiding firms that merely act as intermediaries, which could adversely affect potential compensation outcomes.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, with the class period spanning from January 19 to March 24, 2026, potentially impacting numerous investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials misleadingly claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered losses to submit claims and encouraging witnesses to provide information to assist in the investigation.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading advertising not only undermines investor confidence but also poses a public health risk, as these claims grossly exaggerate Anktiva's benefits.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors urged to apply as Lead Plaintiff by May 26, 2026, highlighting serious concerns regarding corporate governance and compliance.
- FDA Warning Impact: On March 24, 2026, the FDA publicly issued a warning letter to ImmunityBio, asserting misleading promotions of its bladder cancer drug Anktiva, resulting in a 21.12% drop in stock price to $7.41 per share on the same day, reflecting market apprehension about the company's compliance capabilities.
- Law Firm Credentials: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, founded over 85 years ago, and has successfully recovered multimillion-dollar damages for victims, underscoring its authority and influence in the legal field.
- Investor Action Call: Investors are encouraged to contact Pomerantz LLP via email, providing their share purchase details and contact information to participate in the lawsuit, indicating heightened market concern and uncertainty regarding the company's future prospects.
See More
ImmunityBio Faces Class Action Lawsuit from Investors
- Class Action Initiated: Berger Montague has filed a class action lawsuit against ImmunityBio on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's transparency.
- Severe Investor Losses: The lawsuit alleges that Chief Scientific Officer Patrick Soon-Shiong materially overstated the performance of the Anktiva platform, resulting in a more than 21% drop in share price in a single trading session, indicating a loss of market confidence in the company's prospects.
- Investor Deadline for Representation: Investors must apply by May 26, 2026, to be appointed as lead plaintiff representatives, demonstrating a proactive stance in protecting their rights, which could influence the outcome of the litigation.
- Law Firm Background: Berger Montague specializes in complex civil litigation and class actions, having recovered over $50 billion for clients over 55 years, showcasing its strong capabilities and influence in the legal field.
See More
ImmunityBio Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that they must submit lead plaintiff applications for the ImmunityBio securities class action lawsuit by May 26, 2026, covering transactions from January 19 to March 24, 2026, to protect their legal rights.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to financial losses for investors and damage the company's reputation.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, posing potential public health risks.
- Stock Price Plunge: Following this news, ImmunityBio's stock price fell by 21%, decreasing by $1.98 per share to close at $7.42, reflecting market concerns over the company's compliance and future outlook.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, reminding them of the May 26, 2026 deadline to seek lead plaintiff status in a federal securities class action against the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and potential claims options.
- Background of Potential Claims: The investigation arises from possible legal liabilities faced by ImmunityBio, with losses incurred by investors during this period potentially impacting their investment decisions, and Faruqi & Faruqi's involvement aims to assist investors in protecting their rights.
- Importance of Class Action: Participating in a federal securities class action can provide legal support for investors and may enhance the chances of successful claims through collective action, reflecting Faruqi & Faruqi's commitment to safeguarding investor interests.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly overstating Anktiva's capabilities, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its leadership in the field.
- Investor Guidance: Investors are advised to select counsel with a proven track record to ensure optimal representation in class actions, avoiding firms that merely act as intermediaries, which could adversely affect potential compensation outcomes.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, with the class period spanning from January 19 to March 24, 2026, potentially impacting numerous investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials misleadingly claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered losses to submit claims and encouraging witnesses to provide information to assist in the investigation.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading advertising not only undermines investor confidence but also poses a public health risk, as these claims grossly exaggerate Anktiva's benefits.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors urged to apply as Lead Plaintiff by May 26, 2026, highlighting serious concerns regarding corporate governance and compliance.
- FDA Warning Impact: On March 24, 2026, the FDA publicly issued a warning letter to ImmunityBio, asserting misleading promotions of its bladder cancer drug Anktiva, resulting in a 21.12% drop in stock price to $7.41 per share on the same day, reflecting market apprehension about the company's compliance capabilities.
- Law Firm Credentials: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, founded over 85 years ago, and has successfully recovered multimillion-dollar damages for victims, underscoring its authority and influence in the legal field.
- Investor Action Call: Investors are encouraged to contact Pomerantz LLP via email, providing their share purchase details and contact information to participate in the lawsuit, indicating heightened market concern and uncertainty regarding the company's future prospects.
See More
ImmunityBio Faces Class Action Lawsuit from Investors
- Class Action Initiated: Berger Montague has filed a class action lawsuit against ImmunityBio on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's transparency.
- Severe Investor Losses: The lawsuit alleges that Chief Scientific Officer Patrick Soon-Shiong materially overstated the performance of the Anktiva platform, resulting in a more than 21% drop in share price in a single trading session, indicating a loss of market confidence in the company's prospects.
- Investor Deadline for Representation: Investors must apply by May 26, 2026, to be appointed as lead plaintiff representatives, demonstrating a proactive stance in protecting their rights, which could influence the outcome of the litigation.
- Law Firm Background: Berger Montague specializes in complex civil litigation and class actions, having recovered over $50 billion for clients over 55 years, showcasing its strong capabilities and influence in the legal field.
See More
ImmunityBio Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that they must submit lead plaintiff applications for the ImmunityBio securities class action lawsuit by May 26, 2026, covering transactions from January 19 to March 24, 2026, to protect their legal rights.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to financial losses for investors and damage the company's reputation.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, posing potential public health risks.
- Stock Price Plunge: Following this news, ImmunityBio's stock price fell by 21%, decreasing by $1.98 per share to close at $7.42, reflecting market concerns over the company's compliance and future outlook.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, reminding them of the May 26, 2026 deadline to seek lead plaintiff status in a federal securities class action against the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and potential claims options.
- Background of Potential Claims: The investigation arises from possible legal liabilities faced by ImmunityBio, with losses incurred by investors during this period potentially impacting their investment decisions, and Faruqi & Faruqi's involvement aims to assist investors in protecting their rights.
- Importance of Class Action: Participating in a federal securities class action can provide legal support for investors and may enhance the chances of successful claims through collective action, reflecting Faruqi & Faruqi's commitment to safeguarding investor interests.
See More
